

## Special Issue

# Nucleic Acid Nanobiology for Drug Delivery and Immunotherapy

### Message from the Guest Editor

Immunomodulatory nucleic acids have been identified as potent pharmaceuticals, ranging from Toll-Like Receptor (TLR) agonists to checkpoint blockades. Similarly designed DNA agonists have been shown to bind irreversibly to the same receptors to reduce undesirable immune responses. By harnessing the programmable architecture of nucleic acids, dynamic structures can be designed which are capable of carrying out precisely controlled functions and immunomodulation for uses in nanomedicine. The coverage of this special issue will include (but not limited) by following topics:

- Immunorecognition of nucleic acids in animal models and humans
- Desirable immunomodulation using nucleic-acid based nanoparticles
- Undesirable immunological side-effects of nucleic acid therapeutics
- Rational design and characterization of programmable nucleic-acid based nanoparticles
- Delivery of nucleic-acid based nanoparticles and effect of carrier on their immunorecognition
- Therapeutic nucleic-acid based nanoparticles: design, assembly, characterization

Dr. Kirill Afonin

---

### Guest Editor

Dr. Kirill A. Afonin

Department of Chemistry, UNC Charlotte, Charlotte, NC, USA

---

### Deadline for manuscript submissions

closed (31 August 2021)



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/25928](https://mdpi.com/si/25928)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of  
Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore  
- Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).